H.C. Wainwright 6th Annual Israel Conference
Events
Pharmabiotics Online Web Series
Events
Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program
Press Releases
The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next year
Rehovot, Israel – October 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN),
Biomica Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
Press Releases
Rehovot, Israel – September 9, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference.
Positive pre-clinical results for Biomica, Evogene’s subsidiary, in its Immuno-Oncology Program
In The Media
Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program
Press Releases
Biomica’s, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year
Rehovot, Israel – September 8, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,
Biomica has been recognized by IVC Research Center and Grove Ventures, as a Next-Gen Deep Tech startup in the Israeli healthcare ecosystem, together with other innovative startups
In The Media
Pharmabiotics 2020
Events
Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
Press Releases
The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Chardan’s 2nd Annual Microbiome Medicines Summit
Events